BioCentury | Apr 7, 2014
Company News

Opko management update

...Opko's newly created active pharmaceutical ingredient and chemical development division, formerly president and CEO of FineTech Pharmaceutical Ltd....
BioCentury | Jan 2, 2012
Company News

FineTech, Opko deal

...Opko acquired API manufacturer FineTech in a cash and stock deal valued at $27.5 million. Opko...
...shares. FineTech is also eligible for up to $5 million in sales milestones. Opko said FineTech's...
...targeting VEGF mRNA, including new dosing protocols or combination products (see BioCentury, March 9, 2009). FineTech Pharmaceutical Ltd....
Items per page:
1 - 2 of 2
BioCentury | Apr 7, 2014
Company News

Opko management update

...Opko's newly created active pharmaceutical ingredient and chemical development division, formerly president and CEO of FineTech Pharmaceutical Ltd....
BioCentury | Jan 2, 2012
Company News

FineTech, Opko deal

...Opko acquired API manufacturer FineTech in a cash and stock deal valued at $27.5 million. Opko...
...shares. FineTech is also eligible for up to $5 million in sales milestones. Opko said FineTech's...
...targeting VEGF mRNA, including new dosing protocols or combination products (see BioCentury, March 9, 2009). FineTech Pharmaceutical Ltd....
Items per page:
1 - 2 of 2